Recent 8-K filings for PYXS

• May 14, 2026, 7:36 AM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026

  Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.

• April 30, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change ×2

  Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation

  Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.

• March 23, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO

  Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.

• February 6, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO

  Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.

• December 18, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC

  MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.

• November 3, 2025, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026

  Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.

• August 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead

  Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.

• August 4, 2025, 7:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Pyxis Oncology confirms HNSCC enrollment guidance for Phase 1 MICVO trial after ClinicalTrials.gov revision

  Revised ClinicalTrials.gov entry for MICVO (PYX-201) Phase 1 monotherapy trial reflects maximum patient enrollment per protocol.

• July 3, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01

  Pyxis Oncology CFO/COO Pamela Connealy retires; Jitendra Wadhane appointed PFO

  Pamela Connealy, CFO and COO, retired from Pyxis Oncology effective July 1, 2025; not due to any disagreement.

• June 18, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Pyxis Oncology annual meeting elects three directors, ratifies EY auditor

  Elected Dr. Santhosh Palani, Darren Cline, and Dr. Rachel Humphrey as Class I directors until 2028.

• May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025

  Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.

• March 24, 2025, 7:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  Pyxis Oncology posts updated investor presentation; no specific new data disclosed

  Updated corporate presentation dated March 24, 2025, posted on company IR website.

• March 18, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%

  Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.

• February 26, 2025, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Pyxis Oncology receives FDA Fast Track for PYX-201 in head and neck cancer

  FDA granted Fast Track Designation to PYX-201 for recurrent/metastatic HNSCC after prior chemo and anti-PD-(L)1.

• February 4, 2025, 6:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC

  Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.

• December 19, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106

  Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.

• November 20, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo

  PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.

• November 12, 2024, 6:59 PM ET other material materiality 0.60 neutral item 2.02item 9.01

  Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026

  Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.

• October 23, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Pyxis Oncology shareholders approve 5.5M share increase in equity plan at special meeting

  Shareholders voted 23,234,250 to 12,829,636 to approve amendment to 2021 Equity and Incentive Plan adding 5,500,000 shares.

• August 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026

  Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.

• June 12, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Pyxis Oncology stockholders elect four directors, ratify Ernst & Young as auditor

  Dr. Santhosh Palani elected Class I director with 28,241,400 for, 93,674 withheld.

• June 10, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024

  Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.

• May 14, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024

  Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.

• March 27, 2024, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash

  One-time $8M payment from Novartis for rights to Beovu and another asset royalties.

• March 27, 2024, 7:59 PM ET other material materiality 0.35 neutral item 8.01item 9.01

  Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M

  Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).

• March 21, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials

  Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.

• March 13, 2024, 7:59 PM ET leadership materiality 0.35 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  Pyxis Oncology appoints Santhosh Palani, Ph.D., CFA to board; grant of 69,760 options

  Santhosh Palani appointed to Pyxis Oncology board effective March 12, 2024.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

8 positive 0 negative 19 neutral

source · PYXS on sec.gov